Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2016-03-30 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于为控股公司提供担保的公 告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding guarantees provided by the company for its holding subsidiaries. It details the guarantee amounts, the companies involved, their financial status, and the board's opinion on the guarantees. There is no indication of this being a financial report, audit report, or earnings release. The document is a formal announcement about the company's provision of guarantees, which relates to capital or financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it contains substantive information about financing guarantees rather than just announcing a report publication or certification, so it is not RPA or RNS.
2016-03-30 Chinese
独立董事对公司对外担保情况的专项说明及独立意 见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by the independent directors of Kunming Pharmaceutical Group Co., Ltd. regarding the company's external guarantees. It references regulatory notices from the China Securities Regulatory Commission and the Shanghai Stock Exchange related to external guarantees and disclosure requirements. The content details specific guarantee contracts, amounts, terms, and compliance with company articles and listing rules. The document is focused on a specific governance and compliance matter related to external guarantees rather than a full financial report or announcement of voting results. It is not an annual report, audit report, earnings release, or any other financial statement. It is a regulatory compliance disclosure related to governance and external guarantees. Given the nature and length (3666 characters), it is not a report publication announcement but a regulatory filing. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2016-03-30 Chinese
2015年年度报告
Annual Report Classification · 100% confidence The document is titled '2015 年年度报告' which translates to '2015 Annual Report'. It contains detailed sections typical of an annual report such as company overview, financial data, management discussion and analysis, corporate governance, and audited financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial data, risk disclosures, business overview, and detailed financial metrics for the year 2015. The presence of an audit opinion from an accounting firm further supports this classification. Therefore, this document is the official yearly report covering company activity and full financial performance for the fiscal year 2015, fitting the definition of an Annual Report (10-K). FY 2015
2016-03-30 Chinese
独立董事对公司对外担保情况的专项说明及独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by the independent directors of Kunming Pharmaceutical Group Co., Ltd. regarding the company's external guarantees. It references regulatory notices related to external guarantees and provides detailed information about guarantee amounts, terms, and compliance with company articles and listing rules. The document does not contain financial statements or comprehensive financial performance data but focuses on a specific governance-related disclosure about external guarantees and independent directors' opinions. It is not an annual report, audit report, or earnings release. It is not a short announcement of a report but a standalone detailed statement. This fits best under Regulatory Filings (RNS) as it is a regulatory disclosure document that does not fit other specific categories.
2016-03-30 Chinese
东海证券股份有限公司关于公司2015年度募集资金存放与实际使用 情况专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed special verification report by Donghai Securities regarding the storage and actual use of raised funds by Kunming Pharmaceutical Group Co., Ltd. for the year 2015. It includes specific financial data on fundraising amounts, usage, storage, and compliance with regulatory requirements. The document references regulatory guidelines and audit reports, and contains tables with detailed financial figures related to fundraising projects and their progress. The content focuses on the management and use of raised capital, which aligns with a specialized audit or verification report rather than a full annual report or earnings release. The document is not a simple announcement or certification but contains substantive financial and compliance information. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2015
2016-03-30 Chinese
2015年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by Kunming Pharmaceutical Group Co., Ltd. It includes specifics on amounts raised through various stock issuances, the timing of fund receipt, detailed usage of funds, investment projects, and compliance with regulatory requirements. The document references approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange, and includes audit verification reports. The content focuses on the management and actual use of raised capital, including investment projects and cash management of idle funds. This matches the description of a Capital/Financing Update, which covers updates on company fundraising and the use of raised capital. The document is lengthy (15,000 characters) and contains substantive financial and operational data related to capital usage, not just an announcement or summary. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-03-30 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.